Abstract
Phisiological activation of PI3K pathway is necessary for cells to regulate many different physiological processes such as transcription, protein synthesis, metabolic responses and membrane trafficking. Abnormal activation of the PI3K pathway leads to an increased activity resulting in tumor onset, maintenance, progression and invasion. Both genetic and epigenetic alterations could affect the normal pathways activation. Ovarian cancer is the leading cause of death from gynaecological malignancies in the western world. PI3K pathway has been recorded as one of the most deregulated signalling pathway in many tumors, including ovarian ones. So it could be considered an attractive target to be investigated with the various classes of chemical compounds already present or in development. In this rewiew well try to discuss the published data of the inhibitors targeting members of the PI3K/ akt/ mTOR pathway in the ovarian cancer setting from a preclinical and clinical point of view, with particular emphasis on drugs combination and strategies of administration. Relevant issues and limitations to the use of particular compounds will be also addressed.
Keywords: PI3K, mTOR, anti-cancer drugs, drug combination, gynaecological malignancies, Ovarian cancer, malignancy, receptor tyrosine kinases (RTKs), G protein-coupled receptors, phosphorylate phosphoinositides (PIs), Pleckstrin Homology, tuberous sclerosis, signaling nodes, PI3K INHIBITORS, synergistic effects, paclitaxel, carboplatin, tumor xenografts, glucose homeostasis, phosphoinositide, API-2, macrolide Rapamycin, bevacizumab, Topotecan, pegylated doxorubicin, PI3K-like kinase (PIKK), chemotherapy, angiogenesis, hypoxia, metformin, rapalogs, regimens
Current Medicinal Chemistry
Title: PI3K/AKT/mTOR Inhibitors In Ovarian Cancer
Volume: 17 Issue: 36
Author(s): M. Mazzoletti and M. Broggini
Affiliation:
Keywords: PI3K, mTOR, anti-cancer drugs, drug combination, gynaecological malignancies, Ovarian cancer, malignancy, receptor tyrosine kinases (RTKs), G protein-coupled receptors, phosphorylate phosphoinositides (PIs), Pleckstrin Homology, tuberous sclerosis, signaling nodes, PI3K INHIBITORS, synergistic effects, paclitaxel, carboplatin, tumor xenografts, glucose homeostasis, phosphoinositide, API-2, macrolide Rapamycin, bevacizumab, Topotecan, pegylated doxorubicin, PI3K-like kinase (PIKK), chemotherapy, angiogenesis, hypoxia, metformin, rapalogs, regimens
Abstract: Phisiological activation of PI3K pathway is necessary for cells to regulate many different physiological processes such as transcription, protein synthesis, metabolic responses and membrane trafficking. Abnormal activation of the PI3K pathway leads to an increased activity resulting in tumor onset, maintenance, progression and invasion. Both genetic and epigenetic alterations could affect the normal pathways activation. Ovarian cancer is the leading cause of death from gynaecological malignancies in the western world. PI3K pathway has been recorded as one of the most deregulated signalling pathway in many tumors, including ovarian ones. So it could be considered an attractive target to be investigated with the various classes of chemical compounds already present or in development. In this rewiew well try to discuss the published data of the inhibitors targeting members of the PI3K/ akt/ mTOR pathway in the ovarian cancer setting from a preclinical and clinical point of view, with particular emphasis on drugs combination and strategies of administration. Relevant issues and limitations to the use of particular compounds will be also addressed.
Export Options
About this article
Cite this article as:
Mazzoletti M. and Broggini M., PI3K/AKT/mTOR Inhibitors In Ovarian Cancer, Current Medicinal Chemistry 2010; 17 (36) . https://dx.doi.org/10.2174/092986710794182999
DOI https://dx.doi.org/10.2174/092986710794182999 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Surface Markers of Cancer Stem Cells in Solid Tumors
Current Stem Cell Research & Therapy Telomere Length Variations in Aging and Age-Related Diseases
Current Aging Science From Multiple PAR1 Receptor/Protein Interactions to their Multiple Therapeutic Implications
Current Topics in Medicinal Chemistry A proteomics based approach for the identification of gastric cancer related markers
Current Pharmaceutical Design Radioprotective Gene Therapy
Current Gene Therapy “Metabolic Reprogramming” in Ovarian Cancer Cells Resistant to Cisplatin
Current Cancer Drug Targets Synthesis of Coumarin linked Naphthalimide Conjugates as Potential Anticancer and Antimicrobial Agents
Letters in Drug Design & Discovery The Therapeutic Effect of Stem Cells on Chemotherapy-Induced Premature Ovarian Failure
Current Molecular Medicine Stable Expression of the Sodium/Iodide Symporter (NIS) for anti-Cancer Gene Therapy of Glioma Cells Using a Third Generation Self-Inactivating Lentiviral Vector System in Combination with 211At
Current Radiopharmaceuticals Plasminogen Receptors in Human Malignancies: Effects on Prognosis and Feasibility as Targets for Drug Development
Current Drug Targets Ewing’s Sarcoma Cancer Stem Cell Targeted Therapy
Current Stem Cell Research & Therapy LPA and its Analogs-Attractive Tools for Elucidation of LPA Biology and Drug Development
Current Medicinal Chemistry The Therapeutic Aspects of the Endocannabinoid System (ECS) for Cancer and their Development: From Nature to Laboratory
Current Pharmaceutical Design Potentiation of Anti-Cancer Treatment by Modulators of Energy Metabolism
Current Pharmaceutical Biotechnology Profiling of Multiple Signal Pathway Activities by Multiplexing Antibody and GFP-Based Translocation Assays
Combinatorial Chemistry & High Throughput Screening The Endocrine Disruptor Bisphenol A (BPA) Exerts a Wide Range of Effects in Carcinogenesis and Response to Therapy
Current Molecular Pharmacology Lgr5 Contributes to Intestinal Metaplasia During Gastric Carcinogenesis: A Meta analysis
Anti-Cancer Agents in Medicinal Chemistry Clinical and <i>In Silico</i> Outcomes of the Expression of miR-130a-5p and miR-615-3p in Tumor Compared with Non-Tumor Adjacent Tissues of Patients with BC
Anti-Cancer Agents in Medicinal Chemistry Anticancer Potential of Mefenamic Acid Derivatives with Platelet-Derived Growth Factor Inhibitory Property
Anti-Cancer Agents in Medicinal Chemistry Estrogen Receptor Beta in Cancer: an Attractive Target for Therapy
Current Pharmaceutical Design